Which Joe gave his name to ‘sloppy joes’? We look at five interesting sandwiches and their lexical origins.
A biopharmaceutical drug designed to have active properties similar to one that has previously been licensed:‘copycat drug makers use an innovator's research data to make biosimilars’
- ‘Presently the company is developing a biosimilar of the antibody, a drug with dramatic therapeutic effects for rheumatoid arthritis.’
- ‘The drug is being developed as a biosimilar to Herceptin.’
- ‘Expertise in injectables could also help when the market for biosimilars, or copycat biotechnology drugs, opens up.’
- ‘We have no idea at this point whether this biosimilar will prove efficacious.’
- ‘I can add another example, the cost of developing a biosimilar that costs around 30 million.’
- ‘Biosimilars will have to be advertised and explained.’
- ‘Now it's true that some patent expirations expected in the 2011-2013 timeframe have been pushed out, and it's also true that biosimilars could be a sizable opportunity.’
- ‘Based on European experience, Amgen could sell its biosimilar at a price discount of 15-20 percent versus Neupogen upon launch.’
- ‘Since these agents are not considered bioequivalent, the pharmacy cannot substitute a biosimilar for the branded version.’
- ‘The United States wants to learn more about how other TPP countries "address the issue of biologics and biosimilars before proposing any specific provisions," she said.’
- ‘Considerable investment is also needed to produce a biosimilar and bring it to market.’
- ‘Generic drugmakers are pushing into the field of biosimilars as global pharmaceutical companies face the loss of patent protection on many established drugs.’
- ‘FDA has not approved tbo-filgrastim as a biosimilar to Neupogen (filgrastim).’
- ‘The complexity of biosimilars has led to a drawn-out process and more questions posed by the industry.’
- ‘The first-ever approved biosimilar, Omnitrope (somatropin), arrived on the European market in 2006.’
- ‘Patients will either get the biosimilar or actual Rituxan.’
- ‘So far, the only country where a Celltrion-made biosimilar is on the market is South Korea.’
- ‘The process to develop a biosimilar is more complex than that of developing a generic copy of a chemical-based compound.’
- ‘Also discussed in detail are success factors for the emerging biosimilar industry and the regulatory environment in emerging markets with respect to biosimilars.’
- ‘The attractiveness of biosimilars, regardless of the product, is you'll always have limited competition because of the complexity and the investments required to make such medicines.’
Early 21st century: from bio- + similar.
We take a look at several popular, though confusing, punctuation marks.
From Afghanistan to Zimbabwe, discover surprising and intriguing language facts from around the globe.
The definitions of ‘buddy’ and ‘bro’ in the OED have recently been revised. We explore their history and increase in popularity.